_AF_BOSAGAS_80_900x900.png)
Each tablet BOSAGAS 80 contains:
Active ingredient:
| Telmisartan | 80 mg |
Excipients: Lactose monohydrate, sodium carbonate, povidone K30, sodium croscarmellose, magnesium stearate.
Hypertension: Telmisartan could be used as a monotherapy or in combination with other antihypertensive drugs.
Angiotensin II receptor blockers could replace ACE-inhibitors in treatment of heart failure (official indication) or diabetic nephropathy.
DOSAGE AND ADMINISTRATION
Administration: Telmisartan tablets are for once-daily oral administration and should be taken, with or without food.
Dosage
Adults: 40 mg once daily. Some patients may already benefit at a daily dose of 20 mg. The dose of telmisartan can be increased to a maximum of 80 mg once daily if needed. Alternatively, telmisartan may be used in combination with thiazide-type diuretics. When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment.
Renal impairment: No dose adjustment is necessary for patients with renal impairment.
Hepatic impairment: In patients with mild to moderate hepatic impairment, the posology should not exceed 40 mg once daily
Elderly: No dose adjustment is necessary for elderly.
Children: The safety and efficacy of Telmisartan in children and adolescents aged below 18 years have not been established.
CONTRAINDICATIONS
Hypersensitivity to any of the excipients.
Pregnancy and lactation.
Severe renal impairment
Severe hepatic impairment. Biliary obstructive disorders
WARNINGS AND PRECAUTIONS
Monitoring of serum potassium is recommended, especially in the elderly and in patients with renal impairment. Reduce the starting dose in these patients.
Aortic and mitral valve stenosis.
Obstructive hypertrophic cardiomyopathy
Severe congestive heart failure.
Intravascular hypovolemia (volume and sodium depleted by vomiting, diarrhoea, long term diuretic therapy, haemodialysis, dietary salt restriction) may increase the risk of symptomatic hypotension.
Such conditions should be corrected before the administration of telmisartan or reduced dose and closely monitored while administration.
Active gastric ulcer disease or other gastrointestinal disorders
Mild to moderate hepatic impairment
Renal artery stenosis.
Mild to moderate renal impairment
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as telmisartan.
SHELF-LIFE
36 months from the manufacturing date.
Nhà máy: 43 đường số 8, KCN Việt
Nam – Singapore, Phường Bình Hòa, Thành phố Hồ Chí
Minh, Việt Nam. Điện thoại: (0274) 3769 606
Văn phòng và chi nhánh:
- VP Lisbon (Bồ Đào Nha): Campo Grande nº 28, 3.º C, - lisbon, district of Lisbon, municipality of Lisbon, parish of Alvalade.
Điện thoại: 1900 1910
- CN Hà Nội: Số 38 Đức Giang, Phường Việt Hưng, Thành phố Hà Nội, Việt Nam.
Điện thoại: (024) 7305 0606
- CN Đà Nẵng: Số nhà 01, đường Hàm Trung 4, Phường Hải Vân, Thành phố Đà Nẵng, Việt Nam.
Điện thoại: (023) 6730 3737
- CN Nha Trang: Số 29 Thái Thông, Phường Nam Nha Trang, Tỉnh Khánh Hòa, Việt Nam.
Điện thoại: (025) 8730 3969
- VP Hồ Chí Minh: Tầng 4, Tòa nhà Flemington, số 182 Lê Đại Hành, Phường Phú Thọ,
TP. Hồ Chí Minh, Việt Nam.
Điện thoại: (028) 3838 0606
- CN Cần Thơ: S2-3-4-5, đường số 10, Khu dân cư lô số 11C, khu đô thị Nam Cần Thơ, Phường Hưng Phú, Thành phố Cần Thơ, Việt Nam.
Điện thoại: (029) 2730 5959
Giấy ĐKKD số: 3700843113 do Sở Kế Hoạch & Đầu Tư Tỉnh Bình Dương cấp lần đầu ngày 01/11/2007
Người đại diện: Lương Đăng Khoa
0
Kiểm tra đơn hàng
